Volume | 1,707,999 |
|
|||||
News | - | ||||||
Day High | 6.55 | Low High |
|||||
Day Low | 6.4201 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Adma Biologics Inc | ADMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.54 | 6.4201 | 6.55 | 6.46 | 6.54 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,726 | 1,707,999 | $ 6.48 | $ 11,064,730 | - | 3.06 - 6.76 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:05:55 | 1 | $ 6.42 | USD |
Adma Biologics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.48B | 228.22M | - | 258.22M | -28.24M | -0.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Adma Biologics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADMA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.18 | 6.63 | 5.97 | 6.27 | 2,631,748 | 0.24 | 3.88% |
1 Month | 6.57 | 6.76 | 5.895 | 6.32 | 2,359,805 | -0.15 | -2.28% |
3 Months | 5.36 | 6.76 | 5.02 | 5.93 | 2,560,142 | 1.06 | 19.78% |
6 Months | 3.09 | 6.76 | 3.09 | 5.13 | 2,363,558 | 3.33 | 107.77% |
1 Year | 3.56 | 6.76 | 3.06 | 4.51 | 2,249,217 | 2.86 | 80.34% |
3 Years | 1.915 | 6.76 | 1.01 | 2.77 | 2,896,328 | 4.51 | 235.25% |
5 Years | 4.71 | 6.76 | 1.01 | 2.80 | 2,763,078 | 1.71 | 36.31% |
Adma Biologics Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. |